Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation with Tislelizumab and Lenvatinib for Advanced HCC
NCT05897268Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Jun 2023; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05897268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897268.